

The Potential of Synergistic Plant Extracts in Treating Malaria and HIV

Tugonza Akiro F.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Malaria and HIV remain global health challenges, especially in tropical and subtropical regions. Their co-occurrence exacerbates morbidity and mortality, requiring innovative therapeutic approaches. Traditional medicine offers a vast repository of plant-based treatments with promising antimalarial and antiretroviral properties. This review examines the potential of synergistic plant extracts, focusing on their bioactive compounds, mechanisms of action, and synergistic effects. Historical and ethnobotanical knowledge, combined with modern scientific methodologies, underscores the need for comprehensive studies on these extracts. Preclinical and clinical trials have shown encouraging results, but challenges such as dosage standardization, compound interactions, and funding remain. With interdisciplinary research and policy support, plant-based therapies hold promise for combating these diseases. Emphasizing sustainable cultivation, propagation, and integration of traditional knowledge into modern medicine could pave the way for effective, accessible, and affordable treatments.

Keywords: Malaria, HIV/AIDS, Synergistic plant extracts, Ethnobotany, Antimalarial.

INTRODUCTION

Malaria, a febrile illness caused by *Plasmodium* spp., is responsible for extensive morbidity and mortality globally. Members of the *Plasmodium* genus, called parasites, have a complex biology with the capability to invade and destroy host cells. The life cycles of parasites alternate through mosquito vectors and warm-blooded hosts, leading to complex clinical manifestations. For example, persistent infection by *Plasmodium falciparum* causes severe anemia and coagulopathy, leading to the sequestration of the infected cells in various organs. Other associated features include inflammation, obstruction of the renal and retinal capillaries as well as brain damage [1, 2]. The over 40 million individuals currently living with the human immunodeficiency virus infection mainly show progressive depletion of the CD4+ T cells leading to acquired immune deficiency syndrome. Increasing viral load correlates with the progression of immunosuppression, resulting in recurrent infections. Most patients have oral manifestations like herpes zoster virus reactivation, oral candidiasis, and oral hairy leukoplakia, which increases with sliding CD4+ count, while those with extremely low CD4+ counts develop non-Hodgkin's lymphoma and Kaposi's sarcoma. The two diseases combine to form a public health problem of startling proportions. The majority of individuals living in areas rich in plasmodia are coinfecting with HIV, largely in tropical and subtropical countries. The identified limitations to effectively contain the two parasites in different settings have included drug and vaccine resistance, side effects linked to noncompliance, and shortage of trained healthcare workers among others. The situation is compounded by the fact that plasmodia-infected mosquitoes do not transmit HIV. As such, current treatments need to be augmented with active compounds from various backgrounds to counter the increasing resistance of microorganisms to known drugs [3, 4].

Plant Extracts with Antimalarial and Antiretroviral Properties

Plant extracts with co-existing antimalarial and antiretroviral activities endorse the synergy between these traditionally listed plants. *Cinchona officinalis* L., *Croton tiglium* L., *Cryptolepis sanguinolenta*, and *Mitragyna inermis* are some of the famous plants of traditional medicine. These effective plants have the capability of multi-faceted cures as well. Some aromatic plants might also favor dual antiviral and antimicrobial benefits. Allicin from garlic is used against viral HIV and *Plasmodium miracidia*. Phenolic compounds from *Artemisia herba-alba* were similar to those from *Artemisia ethiopica*, two species that show in vitro efficacy against HIV. Through the design of relevant chemical modifications, the major soluble compounds play a significant role in managing and halting both of these critical deadly diseases. Investigations of the chemistry of such medicinal plants concluded the analysis with that of the Sri Lankan *C. zeylanica*. The antimalarial and anti-HIV natural plant extract can be used for comparative studies as it is largely used in Southeast Asia. A clinical trial should also be examined to discover the significance of each particular target and pathway. Respective local pharmacopeias of the indigenous system of Ayurveda and monographs on social aspects exist in the Medicinal Plants Research Institute. In Thailand and Vietnam, the surveyed species are locally important sources for relieving various ailments and are among the most used medicinal plants. Numerous previous reports have also suggested that the consumption of medicinal plants and artemether/lumefantrine-based combination therapy increases efficacy against multiple pathogens, including helminth-malarial co-infections, malaria, and human immunodeficiency virus. Although an array of these anti-infective active plants are extolled in the blossoming but underutilized field of ethnobotany, the current study focuses on scrutinizing the traditionally acclaimed antimalarial plants used in treating malaria and HIV/AIDS. An analysis of such methods and historical background to initiate new therapeutic strategies geared toward treating these two diseases has been conducted. According to the validated plants utilized, nine methods of employing these synergistic antimalarial plants are outlined. The validated medicinal plant extracts were studied for efficacy against chloroquine-sensitive and chloroquine-resistant strains of *Plasmodium falciparum*. Various chemical active compounds of validated plant extracts also exhibit potential anti-HIV activity using docking scores. Therefore, the validated medicinal plant extracts are considered appropriate to treat both AIDS and malaria. An attempt is made here to systematize the options for molecular targets that are suggested to be significant to both *Plasmodium* spp. and HIV/AIDS by the reported literature survey. Dissimilar local systems, wherever possible, were described for efficacy validation [5, 6].

Synergistic Effects of Plant Extract Combinations

The concept of synergism is known in scientific literature as the increased therapeutic effects when using specific combinations of plant extracts. Several mechanisms of action have been identified, such as boosting cells' absorption of drugs acting inside a parasite or immune cells and inhibiting the development of resistance. In different studies, scientists found that for malaria and HIV, synergy between plant extracts can indeed lead to better effects than single extracts. These combinations combine restricted partners and explore different ways that one partner can boost the therapeutic activity of the others. It is also striking to realize that what is found systematically in the agreements between traditional medical practices is that they indeed report combinations. This fact points out the crucial importance of synergistic effects in traditional therapeutic practices, as a concentration of centuries of therapeutic practices. They represent years of valuable knowledge, most of the time only transmitted through oral tradition that should not be neglected [7, 8]. As investigators put it, one obstacle would be to find the right combination to give the right equivalence, i.e., the right ratio/dosage of each of the partners. The question is difficult if you consider as well that, in the case of most studies that exist on the subject of natural products, the majority of them provide little or no information on the number of active compounds or at least the plant extract within the combinations. Furthermore, for practical reasons, the optimal equivalence of two combinations should also minimize the mass of plants in the mixture. The second possible counterweight is the potential confusion between constituents as the composition of plant extracts is extremely complex, and inter- and intra-molecular interactions can lead to unsuspected metabolites and interactions. In classical pharmacology and research, both of these phenomena still appear to be poorly defined and offer an exciting approach to the toxicity and efficacy of mixtures. The importance of the development of techniques for investigating interactions to standardize the dosage and understand the mechanisms placed at the heart of the problem is underscored [9, 10].

Clinical Trials and Future Prospects

A clinical trial is an experiment conducted in people to evaluate the effect of a treatment. Trials can vary between Phase 1 and Phase 4. Phase 1 aims to look at the safety and tolerance of a potential new

treatment, often in healthy people. Phase 2 will look at the effectiveness of the new treatment for a particular disease, and Phase 3 aims to test the new treatment compared to the current standard of care. Very often, combinations of new and old treatments are compared to standard treatment. Finally, Phase 4 is the post-marketing surveillance of approved treatments. These trials are to evaluate how drugs work in the whole patient population [11, 12]. In recent years, there have been a variety of clinical trials that aim to evaluate the ability of plant extracts to treat malaria and HIV. The studies vary between pre-clinical, Phase 1, 2, and 3/4 clinical trials, providing evidence of proven efficacy for possible combination therapies using plant-based treatments. A big consideration is the ethical assessment the study undergoes, and obtaining regulatory and ethical approvals is paramount for any trial for reasons of participant safety and ensuring the likely scientific approaches to be used are sensible to the study hypothesis. It can be challenging to get financial support to fund studies in resource-poor settings and in diseases that are of limited importance to high-income countries [13, 14, 15]. Training is also an important aspect that should be considered as part of the burden of non-communicable and communicable diseases facing low- and middle-income countries. One in every six patients admitted to emergency departments in sub-Saharan Africa is HIV-infected. Ongoing safety studies can be expensive, and slow, and may follow ethical and clinical issues that restrict the follow-on clinical development of a potentially promising intervention [16, 17, 18]. Despite there being such clinical studies taking place at the moment, further research is always required; for example, more efficient and systematic methods are needed to assess dosing and modes of delivery [19, 20]. A number of the current trials are limited to one geographical region or even a single site, meaning that evidence from multiple different settings is required if the use of plant extracts is to expand more broadly. Such evidence of reproducibility can also help develop new therapies for preventing deaths and improving health, and ultimately be transferred into public health policy. To conduct such studies, large governmental and non-governmental funding contributions are necessary [20, 21, 22]. To advance policies that promote the use of plant-based treatments, evidence from a variety of study designs is required in a variety of settings. Success in this field is likely to require academic, industry, and government as well as non-government partnerships. As the therapies that are likely to be developed under such a research agenda might be used in pregnancy, including studies of safety should be a routine practice [23].

RECOMMENDATIONS

This review summarizes the scientific understanding of the potential of synergistic plant extracts as antimalarials in monotherapy or combination therapy to treat HIV and its co-infections. The review has substantiated that researchers have identified four bioactive compounds or mixtures from traditional medicines based on an ethnobotanical approach. From a leading concept perspective, new therapies are urgently needed because increasingly resistant pathogens are spreading in the world due to the limited efficacy of the currently used drugs, the inability to establish long-term immunity, and the high cost of new therapeutics, which are far from being realized [15, 16]. Although several bioactive plant compounds have been reported to have high potential, presently, there are only five patents on the development of monotherapies and nine patents on the envisaged joint medicines for malaria and HIV available. It is therefore highly recommended to conduct integrated, interdisciplinary studies in standard science on ethnomedicines, particularly phytochemical screening, toxicology, in vitro and in vivo biological studies, preclinical stages, and finally clinical trials. Importantly, for their wider acceptance in combating the twin global health scourges of malaria infection and HIV infection at the public health policy level, conducting awareness campaigns and training of healthcare providers, researchers, and society is suggested. The research findings provide a strong recommendation for policy support for the cultivation, propagation, and conservation of medicinal plants, as well as for the traditional medicine systems, which is urgent to recognize by international health policymakers, legal quarters, and plant conservation agencies to meet international standards and global socio-political responsibility. Therefore, the need for an alternative treatment is highly recommended, as this model could bring value addition to the community. From the patent library data, it is clear that research did not take into account that this dynamic medicinal plant is explored through divergent thinking. As a contradiction, the avenue of producing effective and safe novel therapeutic agents from optimal natural compounds is wide open for further exploration. In this research, the confluence of knowledge, science, and need can be fulfilled. In the coming years, herbal and traditional knowledge has the potential to deliver beneficial botanicals to the healthcare market. Combining old knowledge with new ideas would catalyze the development of successful treatments and promote health, particularly in regions currently under high threat. Therefore, the plant-focused production of synergistic extracts will be the way to create the next generation of medicines [17, 18].

CONCLUSION

The synergistic use of plant extracts offers a compelling avenue for addressing the dual global health crises of malaria and HIV. This review highlights the potential of bioactive compounds derived from traditional medicinal plants to provide multifaceted therapeutic effects. Despite significant progress, the need for extensive interdisciplinary research remains paramount. Key recommendations include conducting phytochemical screenings, toxicology studies, and preclinical and clinical trials, along with standardizing extraction and dosage methods. Public health strategies should promote the sustainable cultivation and conservation of medicinal plants, integrating traditional medicine systems with modern scientific approaches. Policy-level interventions and awareness campaigns are essential to recognize and harness the value of ethnomedicines. Funding and collaborations across academia, industry, and governments are crucial to advancing this promising field. By merging traditional knowledge with innovative scientific techniques, plant-based therapies can potentially deliver accessible, safe, and effective treatments, especially for underserved regions. The future of medicine lies in the confluence of old wisdom and discoveries, promising hope for those at the greatest risk.

REFERENCES

1. Balaji SN, Deshmukh R, Trivedi V. Severe malaria: Biology, clinical manifestation, pathogenesis and consequences. *Journal of Vector-Borne Diseases*. 2020 Jan 1;57(1):1-3. www.com
2. Liu Q, Yan W, Qin C, Du M, Liu M, Liu J. Millions of excess cases and thousands of excess deaths of malaria occurred globally in 2020 during the COVID-19 pandemic. *Journal of Global Health*. 2022;12.
3. Onyenekwe CC, Ukibe N, Meludu SC, Ilika A, Aboh N, Ofiaeli N, Ezaeni M, Onochie AJ. Prevalence of malaria as co-infection in HIV-infected individuals in a malaria endemic area of southeastern Nigeria. *Journal of Vector Borne Diseases*. 2007 Dec 1;44(4):250.
4. Kotepui KU, Kotepui M. Prevalence of and risk factors for *Plasmodium* spp. co-infection with hepatitis B virus: a systematic review and meta-analysis. *Malaria Journal*. 2020 Dec;19:1-7.
5. Halder M, Jha S. Medicinal plants and bioactive phytochemical diversity: a fountainhead of potential drugs against human diseases. In *Medicinal Plants: Biodiversity, Biotechnology and Conservation* 2023 Jul 8 (pp. 39-93). Singapore: Springer Nature Singapore. [\[HTML\]](#)
6. Ahmad SR, Tamang M. Study of indigenous medicinal plants of northeast states of India as potential therapies for Malaria. *Biosciences Biotechnology Research Asia*. 2020 Sep 1;17(3):567. researchgate.net
7. Antony A, Farid M. Effect of temperatures on polyphenols during extraction. *Applied Sciences*. 2022 Feb 17;12(4):2107.
8. Ali O, Ramsubhag A, Jayaraman J. Biostimulant properties of seaweed extracts in plants: Implications towards sustainable crop production. *Plants*. 2021 Mar 12;10(3):531.
9. Alrefae SH, Rhee KY, Verma C, Quraishi MA, Ebenso EE. Challenges and advantages of using plant extract as inhibitors in modern corrosion inhibition systems: Recent advancements. *Journal of Molecular Liquids*. 2021 Jan 1;321:114666. [\[HTML\]](#)
10. Balekundri A, Mannur V. Quality control of the traditional herbs and herbal products: a review. *Future Journal of Pharmaceutical Sciences*. 2020 Dec;6:1-9.
11. Ban M, Yue X, Dou P, Zhang P. The Effects of Yoga on Patients with Parkinson's Disease: A Meta-Analysis of Randomized Controlled Trials. *Behavioural neurology*. 2021;2021(1):5582488.
12. Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. *Jama*. 2021 Apr 13;325(14):1414-25. jamanetwork.com
13. Laher AE, Venter WD, Richards GA, Paruk F. Profile of presentation of HIV-positive patients to an emergency department in Johannesburg, South Africa. *Southern African Journal of HIV Medicine*. 2021;22(1). ajol.info
14. Rao A, Kennedy C, Mda P, Quinn TC, Stead D, Hansoti B. Patient acceptance of HIV testing services in rural emergency departments in South Africa. *Southern African Journal of HIV Medicine*. 2020;21(1):1-9. scielo.org.za
15. Uwineza PA, Waśkiewicz A. Recent advances in supercritical fluid extraction of natural bioactive compounds from natural plant materials. *Molecules*. 2020 Aug 24;25(17):3847.

16. Kalimuthu AK, Panneerselvam T, Pavadai P, Pandian SR, Sundar K, Murugesan S, Ammunje DN, Kumar S, Arunachalam S, Kunjiappan S. Pharmacoinformatics-based investigation of bioactive compounds of Rasam (South Indian recipe) against human cancer. Scientific reports. 2021 Nov 2;11(1):21488. [nature.com](https://doi.org/10.1038/s41598-021-01488-8)
17. Rotimi K, Fagbemi B, Itiola AJ, Ibinaiye T, Aidenagbon A, Dabes C, Biambo AA, Iwegbu A, Onabajo S, Oguoma C, Oresanya O. Private sector availability and affordability of under 5 malaria health commodities in selected states in Nigeria and the Federal Capital Territory. Journal of Pharmaceutical Policy and Practice. 2024 Dec 31;17(1):2294024. [tandfonline.com](https://doi.org/10.1016/j.jpp.2024.2294024)
18. Rasmussen C, Alonso P, Ringwald P. Current and emerging strategies to combat antimalarial resistance. Expert Review of Anti-infective Therapy. 2022 Mar 4;20(3):353-72. [tandfonline.com](https://doi.org/10.1080/14737175.2022.2081111)
19. Ugwu OPC, Nwodo OFC, Joshua PE, Odo CE, Bawa A, Ossai EC, Adonu CC. Anti-malaria and hematological analyses of ethanol leaf extract of *Moringa oleifera* on malaria infected mice. Int J Pharm Biol Sci. 2013;3(1):360-371.
20. Ugwu OPC, Nwodo OFC, Joshua PE, Odo CE, Ossai EC, Abubakar B. Ameliorative effects of ethanol leaf extract of *Moringa oleifera* on the liver and kidney markers of malaria infected mice. 2013;2(2):43-52.
21. Ugwu OPC, Nwodo OFC, Joshua PE, Odo CE, Ossai EC. The effect of ethanol leaf extract of *Moringa oleifera* on the lipid profile of malaria infected mice. J Appl Sci. 2013;4(1):1324-1332.
22. Enechi OC, Okpe CC, Ibe GN, Omeje KO, Ugwu OPC. Effect of *Buchholzia coriacea* methanol extract on haematological indices and liver function parameters in *Plasmodium berghei*-infected mice. Global Veterinaria. 2016;16(1):57-66.
23. Ugwu OPC. Anti-malaria effect of ethanol extract of *Moringa oleifera* (Agbaji) leaves on malaria induced mice. University of Nigeria Nsukka; 2011:39.

CITE AS: Kungu Erisa (2024). The Potential of Synergistic Plant Extracts in Treating Malaria and HIV. EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH, 7(2):158-162.